BsUFA III regulatory science pilot offers progress report, fields stakeholder criticisms and questions

This week, FDA and its grantees briefed stakeholders on the status of research projects funded through the Biosimilar User Fee Act (BSUFA III) Regulatory Science Pilot Program. The agency continues to refine research goals while racing the programmatic clock, with meeting participants raising concerns about transparency and limited industry input.

Fill out the form to read the full article.